Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal oxybutynin: for overactive bladder.

Lynne M Bang1, Stephanie E Easthope, Caroline M Perry

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|September 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Transdermal oxybutynin effectively treats overactive bladder by reducing incontinence episodes and improving bladder control. This method offers a well-tolerated alternative to oral medications, with fewer anticholinergic side effects.

Area of Science:

  • Pharmacology
  • Urology
  • Dermatology

Background:

  • Oxybutynin is a muscarinic antagonist targeting M3 receptors on the detrusor muscle.
  • Transdermal drug delivery systems offer sustained release over 3-4 days.
  • Overactive bladder (OAB) is characterized by urinary incontinence and urgency.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of transdermal oxybutynin for OAB treatment.
  • To compare transdermal oxybutynin with placebo, oral oxybutynin, and oral tolterodine.

Main Methods:

  • A large, randomized, double-blind trial comparing transdermal oxybutynin 3.9 mg/day to placebo.
  • Assessment of incontinence episodes, micturition frequency, and voided volume.
  • Evaluation of adverse events, particularly anticholinergic effects and application site reactions.

Related Experiment Videos

Main Results:

  • Transdermal oxybutynin significantly reduced weekly incontinence episodes compared to placebo (p=0.0165).
  • Treatment led to decreased micturition frequency and increased average voided volume.
  • Clinical efficacy was comparable to oral oxybutynin and tolterodine.
  • Transdermal oxybutynin was well-tolerated, with mild-to-moderate application site reactions being most common.

Conclusions:

  • Transdermal oxybutynin is an effective treatment for overactive bladder.
  • The transdermal system demonstrates a favorable tolerability profile, with reduced anticholinergic side effects compared to oral formulations.
  • Sustained drug delivery via transdermal patch provides therapeutic concentrations and improves OAB symptoms.